Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, Iowa.
Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, Iowa.
Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):584-9. doi: 10.1016/j.ijrobp.2014.03.008. Epub 2014 May 3.
To determine the risk of radiation-induced malignancy after prophylactic treatment for heterotopic ossification (HO).
A matched case-control study was conducted within a population-based cohort of 3489 patients treated either for acetabular fractures with acetabular open reduction internal fixation or who underwent total hip arthroplasty from 1990 to 2009. Record-linkage techniques identified patients who were diagnosed with a malignancy from our state health registry. Patients with a prior history of malignancy were excluded from the cohort. For each documented case of cancer, 2 controls were selected by stratified random sampling from the cohort that did not develop a malignancy. Matching factors were sex, age at time of hip treatment, and duration of follow-up.
A total of 243 patients were diagnosed with a malignancy after hip treatment. Five patients were excluded owing to inadequate follow-up time in the corresponding control cohort. A cohort of 238 cases (control, 476 patients) was included. Mean follow-up was 10 years, 12 years in the control group. In the cancer cohort, 4% of patients had radiation therapy (RT), compared with 7% in the control group. Of the 9 patients diagnosed with cancer after RT, none occurred within the field. The mean latency period was 5.9 years in the patients who received RT and 6.6 years in the patients who did not. Median (range) age at time of cancer diagnosis in patients who received RT was 62 (43-75) years, compared with 70 (32-92) years in the non-RT patients. An ad hoc analysis was subsequently performed in all 2749 patients who were not matched and found neither an increased incidence of malignancy nor a difference in distribution of type of malignancy.
We were unable to demonstrate an increased risk of malignancy in patients who were treated with RT for HO prophylaxis compared with those who were not.
确定预防异位骨化(HO)治疗后辐射诱发恶性肿瘤的风险。
在 1990 年至 2009 年接受髋臼切开复位内固定治疗髋臼骨折或全髋关节置换术的人群中,进行了一项基于人群的病例对照研究。通过记录链接技术,从我们的州健康登记处确定了被诊断患有恶性肿瘤的患者。从队列中排除有恶性肿瘤病史的患者。对于每例记录的癌症病例,通过分层随机抽样从未发生恶性肿瘤的队列中选择 2 名对照。匹配因素为性别、髋关节治疗时的年龄和随访时间。
共有 243 例患者在髋关节治疗后被诊断患有恶性肿瘤。由于相应对照队列中随访时间不足,排除了 5 例患者。纳入了 238 例病例(对照组,476 例患者)。平均随访时间为 10 年,对照组为 12 年。在癌症队列中,4%的患者接受了放射治疗(RT),而对照组为 7%。在接受 RT 的 9 例癌症患者中,均未发生在照射野内。接受 RT 的患者的平均潜伏期为 5.9 年,未接受 RT 的患者为 6.6 年。接受 RT 的患者癌症诊断时的中位(范围)年龄为 62(43-75)岁,而未接受 RT 的患者为 70(32-92)岁。随后对所有 2749 名未匹配的患者进行了一项特别分析,未发现恶性肿瘤发病率增加,也未发现恶性肿瘤类型分布的差异。
与未接受 RT 治疗 HO 预防的患者相比,接受 RT 治疗的患者恶性肿瘤风险并未增加。